CoChat

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

Open access

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

AIMS/HYPOTHESIS: Traditional blood glucose lowering agents do not prevent the progressive loss of beta cell function in patients with type 2 diabetes. The dipeptidylpeptidase (DPP)-4 inhibitor vildagliptin improves beta cell function both acutely and chronically (up to 2 years). Whether this effect persists after cessation of treatment remains unknown. Here, we assessed the insulin secretory capacity in drug-naive patients with type 2 diabetes after a 52 week treatment period with vildagliptin or placebo, and again after a 12 week washout period. METHODS: This study was conducted at a single university medical centre, and was a double-blind, randomised clinical trial in 59 drug-naive patients with type 2 diabetes and mild hyperglycaemia to either vildagliptin 100 mg (n = 29) or placebo (n = 30). Randomisation was performed by a validated 1:1 system. Neither patient, nor caregiver, was informed about the assigned treatment. Inclusion criteria were drug-naive patients ≥30 years, with HbA(1c) ≤7.5% and BMI of 22-45 kg/m(2). The mildly hyperglycaemic patient population was chosen to minimise glucose toxicity as a confounding variable. Beta-cell function was measured during an arginine-stimulated hyperglycaemic clamp at week 0, week 52 and after a 12 week washout period. All patients with at least one post-randomisation measure were analysed (intent-to-treat). RESULTS: Fifty-two week vildagliptin 100 mg (n = 26) treatment increased the primary efficacy variable, combined hyperglycaemia and arginine-stimulated C-peptide secretion (AIR(arg)), by 5.0 ± 1.8 nmol/l × min, while it decreased by 0.8 ± 1.8 nmol/l × min with placebo (n = 25) (between-group difference p = 0.030). No significant between-group difference in AIR(arg) was seen after the 12 week washout period. The between-group difference adjusted mean 52 week changes from baseline was -0.19 ± 0.11, p = 0.098 and -0.22 ± 0.23%, p = 0.343 for HbA(1c) and fasting plasma glucose, respectively. There were no suspected drug treatment-related serious adverse events. CONCLUSIONS/INTERPRETATION: One year treatment with vildagliptin significantly increased beta cell secretory capacity. This effect was not maintained after the washout, indicating that this increased capacity was not a disease modifying effect on beta cell mass and/or function. TRIAL REGISTRATION: ClinicalTrials.gov NCT00260156.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-011-2167-8

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Relationship between the insulin secretion rate and increasing glucose concentration
Fig. 1 Relationship between the insulin secretion rate and increasing glucose concentrationCC BY-NC · PubMed Central
Fig. 2 Protocol flow-chart and patient disposition
Fig. 2 Protocol flow-chart and patient dispositionCC BY-NC · PubMed Central
Fig. 3 HbA1c (a) and fasting plasma glucose (b) profiles during the treatment period; C-peptide concentrations during hyperglycaemic clamp at week 52, on-drug (c) and week 64, off-drug (d); change from pre-treatment in combined hyperglycaemic and arginine-stimulated C-peptide secretion (e), and disposition index (f), in the vildagliptin and placebo treated group. Data represent mean (SEM) in a–d and adjusted LS mean (SEM) in e–f. AIRarg, C-peptide response to arginine at 15 mmol/l glucose concentration; DI, disposition index. See the Methods section for calculations of beta cell function measures. Black circles and black bars, vildagliptin 100 mg daily; white circles and white bars, placebo
Fig. 3 HbA1c (a) and fasting plasma glucose (b) profiles during the treatment period; C-peptide concentrations during hyperglycaemic clamp at week 52, on-drug (c) and week 64, off-drug (d); change from pre-treatment in combined hyperglycaemic and arginine-stimulated C-peptide secretion (e), and disposition index (f), in the vildagliptin and placebo treated group. Data represent mean (SEM) in a–d and adjusted LS mean (SEM) in e–f. AIRarg, C-peptide response to arginine at 15 mmol/l glucose concentration; DI, disposition index. See the Methods section for calculations of beta cell function measures. Black circles and black bars, vildagliptin 100 mg daily; white circles and white bars, placeboCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 83

Metadata

Authors
Foley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M.
Affiliations
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Amsterdam Public Health (NL)
  • Novartis (Switzerland) (CH)
  • Eli Lilly (United States) (US)
Corresponding author
Foley, J. E.
Venue
Diabetologia
Published
2011-05-06
Volume
54
Issue
8
Pages
1985-1991
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2118830784
Cited by
83
References
13
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 5 · 2017: 8 · 2016: 7 · 2015: 8 · 2014: 19 · 2013: 5 · 2012: 13
FWCI
10.74
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Diabetologia (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
Vrije Universiteit Amsterdam
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
vildagliptin, DPP-4 inhibitors, beta-cell function, type 2 diabetes, insulin secretion, C-peptide, washout period, drug-naive patients, glucotoxicity, insulin resistance, HOMA-IR, HbA1c
MeSH terms
Vildagliptin, Adamantane, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Fasting, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Nitriles, Pyrrolidines, Treatment Outcome, Insulin-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. https://app.cochat.ai/papers/10.1007/s00125-011-2167-8
The paper
Foley, J. E., Bunck, M. C., Möller-Goede, D. L., Poelma, M., Nijpels, G., Eekhoff, E. M., Schweizer, A., Heine, R. J., & Diamant, M. (2011). Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia. https://doi.org/10.1007/s00125-011-2167-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.